potential COVID-19 treatments living meta-analysis of clinical studies

demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only

	COVID 19 hospitalized
	COVID 19 hospitalized	COVID 19 all comers	COVID-19 mild to moderate	COVID-19 severe or critically
potential COVID-19 treatments
adjuvant therapies
anticoagulant
anticoagulant, curative dose	COALIZAO ACTION		ATTACC, ACTIV-4a, and REMAP-CAP ...	REMAP-CAP, ACTIV-4a, ATTACC ... COVID-PACT
anticoagulation, intermediate prophylactic dose				INSPIRATION
heparin at therapeutic dose			RAPID ...
anti-inflammatoty and immuno-therapy
anti-inflammatory therapies
anti GM-CSF
mavrilimumab	MASH-COVID ...
clarithromycine			Rashad ...
colchicine	COLCOVID Salehzadeh GRECCO-19 RECOVERY ... Horby		COL-COVID ...
Colchicine plus rosuvastatin	Gaitan-Duarte ...
non-steroidal anti-inflammatory drugs
Indomethacin			Ravichandran
stem cells	Lanzoni Carmenate ...			Shu Shi
corticosteroids
dexamethasone	RECOVERY dexamethasone			DEXA-COVID19 CODEX ... Jamaati
Dexamethasone 12mg				COVID STEROID 2
Hydrocortisone				CAPE-COVID Munch ...
methylprednisolone	Tang X Metcovid Ranjbar			Steroids-SARI
Immunostimulants drugs
convalescent plasma treatment	ConCOVID ... ConPlas-19 COP-COVID-19 CONTAIN COVID-19 PC/COVID-19 NCT04397757 CONCOR-1 NCT04442191 DAWN-Plasma NCT04385199 COPLA-II trial NCT04403477 ... ASCOT RECOVERY ... CONFIDENT PERUCONPLASMA Bennett-Guerrero Salman Kirenga Co-CLARITY NCT04528368 Holm K CCAP-2 Baldeon Menichetti	LIFESAVER	Libster	CP-COVID-19 Li Rasheed O’Donnell PlasmAr CAPSID AlQahtani REMAP-CAP ... RECOVER Pouladzadeh Sekine ...
Early convalescent plasma.	Balcells
immunoglobulin therapy	Sakoulas			Tabarsi Raman
interferon
IFN beta-1a	SOLIDARITY ...			Darazam ... Kalil ...
high-dose IFN beta-1a	Darazam
IFN beta-1b				Rahmani Darazam ...
inhaled interferon
IFN alpha
pegylated interferon-α2b			Pandit Shashi Bhushan
recombinant super-compound interferon rSIFN-co	Li
SNG001 inhaled interferon beta	Synairgen SG016
interferon / TFF2			Fu
peginterferon			Jagannathan
PNB001			Lattmann
neutralizing antibody	ITAC
amubarvimab/romlusevimab (BRII-196 and BRII-198-Brii Biosciences)	ACTIV-3 ...
bamlanivimab monotherapy	ACTIV-3/TICO LY-CoV555
casirivimab/imdevimab (Ronapreve)	RECOVERY ...		Somersan-Karakaya ...
cilgavimab and tixagevimab (Evusheld)	ACTIV-3/TICO ...
equine polyclonal antibodies INM005				Lopardo
sotrovimab (Xevudy; VIR-7831)	ACTIV-3/ TICO ...
Immunosuppressants drugs
adalimumab				Fakharian
anakinra	SAVE-MORE		CORIMUNO-ANA-1
anti-interleukin-6
Levilimab				V.Lomakin ...
sarilumab	CORIMUNO-SARI-1 ...			sarilumab Sanofi phase 3 outside US
sarilumab high dose (400mg)				Lescure ...
sarilumab low dose (200mg)				Lescure ...
tocilizumab	Dongsheng Wang RCT-TCZ-COVID-19 EMPACTA RECOVERY Soin AS ... Rutgers NCT04412772 ... Declercq J ... NCT04577534 ... EU-CTR2020-001375-32 ... EU-CTR2020-001748-24 ... NCT04479358 ... NCT04434717 ...	BACC Bay Tocilizumab Trial		MARIPOSA COVACTA ... CORIMUNO-TOCI-1 ... REMAP-CAP ... Veiga Talaschian CORIMUNO-TOCI-ICU ... Rosas ...
canakinumab	Sheng ...			CAN-COVID
janus kinase (JAK) inhibitor
baricitinib	COV-BARRIER ACTT-2 ...	RECOVERY		COV-BARRIER ...
ruxolitinib				Cao
TD-0903
TD-0903 10mg				Singh ...
TD-0903 1mg				Singh ...
TD-0903 3mg				Singh ...
tofacitinib	STOP-COVID ...
lenzilumab			LIVE-AIR ...
Kinase inhibitors
imatinib				Aman
leflunomide		Wang
antiandrogenic
progesterone			Ghandehari
antiviral and associated therapy
azithromycin	Sekhavati RECOVERY ...		COALITION I Covid-19 Brazil ... Rashad A ...	COALITION II Covid-19 Brazil ...
azvudine			Ren
baloxavir marboxil	Lou Y
bromhexine			Li T
chloroquine and derivatives
chloroquine	Huang
hydroxychloroquine	HAHPS ORCHID RECOVERY SOLIDARITY ... Chen NO COVID-19 ... Abd-Elsalam TEACH HYCOVID Gonzalez ...	NOR-Solidarity ...	Coalition Covid-19 Brazil I ... FACCT Trial	HYDRA ...
Emtricitabine/tenofovir plus colchicine plus rosuvastatin	Gaitan-Duarte ...
Ensitrelvir (XOCOVA)			Mukae - Phase 2a
favipiravir	Udwadia AVIFAVIR	Lou ... Chang Chen et al. NCT04310228-FAVI ...	Dabbous HM FACCT Trial Udwadia AVIFAVIR NCT04542694 Ruzhentsova T Solaymani-Dodaran Shinkai
favipiravir plus interferon			Khamis
hydroxychloroquine plus macrolides
azithromycin plus hydroxychloroquine	ProPAC-COVID		Coalition Covid-19 Brazil I ...
ivermectin	Gonzalez ...		Shahbaznejad Chaccour Kirti Krolewiecki I-TECH ...	Galan Galan
ivermectin plus doxycycline	Hashim A		NCT04523831 ...
lopinavir/ritonavir	RECOVERY SOLIDARITY ... Nojomi Ader ...		ELACOI ...	Cao REMAP-CAP ...
Lopinavir/ritonavir plus hydroxychloroquine				REMAP-CAP ...
lopinavir/ritonavir plus interferon ß-1a	Ader ...
lopinavir/ritonavir, ribavirin and interferon beta-1b			Hung et al.
niclosamide	Abdulamir
remdesivir	NIH NIAID ACTT-1 DisCoVeRy ... SOLIDARITY ... Mahajan	Norwegian NOR study ... Andreas ...	GS-US-540-5774, 10 days GS-US-540-5774, 5 days GS-US-540-5773 ...	CAP-China ...
sofosbuvir	Alavi-moghaddam
sofosbuvir and daclatasvir	Sadeghi Yakoot Mobarak S ...
sofosbuvir and ledipasvir	Elgohary		Nourian A
tenofovir/emtricitabine	Gaitan-Duarte ...
umifenovir (arbidol)	Nojomi	ELACOI ...	ELACOI ...
Drugs for acid related disorders
H2 blockers
famotidine	Samimagham
miscellaneous
Aspirin	RECOVERY ...
camostat mesilate		Gunst JD
Cannabidiol			Crippa ...
pyridostigmine				Fragoso-Saavedra ...
sabizabulin			VERU-111
Oral antidiabetic drugs
DPP-4 inhibitor				Abuhasira
Renin-angiotensin-system-acting agents
angiotensin receptor blockers (ARBs)	Nouri-Vaskeh
losartan		University of Minnesota
discontinuation of ACEI/ARB			Lopes ...
Vitamins
vitamin C				Zhang
Vitamin D	Entrenas ... Murai

74 studies excluded by filtering options 0

4909	Lee, 2004	0	1	0	selection pending
4910	Soo, 2004	0	0	0	selection pending
4911	HKU/UCH SARS Study Group, 2004	0	0	0	selection pending
4912	Chan, 2003	0	0	0	selection pending
4913	Beigel, 2018	0	1	0	selection pending
5092	Yang, 2020	1	13	3		not a RCT	high risk of bias
5228	Bean, 2020	1	19	3		not a RCT	high risk of bias
5295	Zhang, 2020	1	13	3		not a RCT	high risk of bias
5331	Li, 2020	1	13	4		not a RCT	high risk of bias
5332	Meng, 2020	1	13	4		not a RCT	high risk of bias
5345	Yan et al., 2020	1	20	4		not a RCT	high risk of bias
5346	Mancia, 2020	1	20	3		not a RCT	high risk of bias
5347	Mehra, 2020	2	12	4	excluded	not a RCT	high risk of bias
5348	Reynolds (COVID positive patient), 2020	1	13	3		not a RCT	high risk of bias
5349	Reynolds (prophylaxis), 2020	1	13	3		not a RCT	high risk of bias
5370	Khera (outpatients), 2020	1	13	3		not a RCT	high risk of bias
5372	Khera (inpatients), 2020	1	13	3		not a RCT	high risk of bias
5399	Northwell Consortium (Richardson), 2020	0	99	0	selection pending
5440	Morales, 2020	1	13	0		not a RCT	risk of bias not avaialble
5442	Mancia, 2020	0	0	0	selection pending
5521	Del Amo, 2020	2	0	0	excluded		risk of bias not avaialble
5532	Fosbøl, 2020	0	0	0	selection pending
5604	Schneeweiss, 0	0	13	0	selection pending
5605	Vila-Corcole, 0	0	13	0	selection pending
5619	Pan, 2020	0	13	0	selection pending
5629	Fosbol, 2020	0	0	0	selection pending
5797	Rossi, 0	0	13	0	selection pending
5903	Anzola, 2020	0	10	0	selection pending
6660	Bae, 2021	0	12	0	selection pending
6729	Shah, 2021	1	13	3		not a RCT	high risk of bias
6788	Waissengrin, 2021	0	13	0	selection pending
6790	Pawlowski, 2021	1	13	0		not a RCT	risk of bias not avaialble
6857	Anderson, 2020	0	0	0	selection pending
6894	Andrejko, 2021	1	20	0		not a RCT	risk of bias not avaialble
6927	Rossman, 2021	0	13	0	selection pending
6931	Yair, 2921	1	32	0		not a RCT	risk of bias not avaialble
6934	Boyarsky, 2021	1	32	0		not a RCT	risk of bias not avaialble
6949	Pawlowski, 2021	1	13	0		not a RCT	risk of bias not avaialble
6981	Public Health England (Harris), 2021	1	13	3		not a RCT	high risk of bias
7025	Haberman, 2021	0	13	0	selection pending
7055	Shroff, 2021	0	0	0	selection pending
7070	PHE variants (Technical briefing 12 22 may 2021), 2021	2	20	2	excluded	not a RCT
7325	Skowronski, 2021	0	13	0	selection pending
7419	Scotland delta (Sheikh), 2021	1	20	3		not a RCT	high risk of bias
7420	PHE (Stowe), 2021	2	13	3	excluded	not a RCT	high risk of bias
7940	Wall, 2021	0	0	0	selection pending
7950	Harris, 2021	1	13	3		not a RCT	high risk of bias
8143	Butt, 2021	1	20	2		not a RCT
8147	Canada (Nasreen), 2021	1	20	2		not a RCT
8149	PHE Technical briefing 16 (11/18 June 2021), 2021	2	13	3	excluded	not a RCT	high risk of bias
8150	Ramasamy, 2021	0	32	0	selection pending
8163	Israel delta press release, 0	1	0	0			risk of bias not avaialble
8164	Public Health England, May 16, 2021 (Bernal), 2021	1	20	2		not a RCT
8255	REACT-SCOT, 2021	1	20	0		not a RCT	risk of bias not avaialble
8272	Martinez-Baz, 2021	1	13	0		not a RCT	risk of bias not avaialble
8274	REACT-1 round 13 final report (Elliott, Imperial College London), 2021	1	13	3		not a RCT	high risk of bias
8275	Musser, 2021	2	13	0	excluded	not a RCT	risk of bias not avaialble
8294	CDC Mesa County, Colorado, 2021	1	13	3		not a RCT	high risk of bias
8313	Bahl (Fully vaccinated vs unvaccinated), 2021	0	10	0	selection pending
8350	Rosenberg, 2021	2	13	0	excluded	not a RCT	risk of bias not avaialble
8359	Oxford (Pouwels), 2021	1	13	2		not a RCT
8360	HEROES-RECOVER (Fowlkes), 2021	1	13	3		not a RCT	high risk of bias
8513	Grannis, 2021	1	20	3		not a RCT	high risk of bias
8514	VA (Bajema), 2021	1	20	3		not a RCT	high risk of bias
8515	Scobie, 2021	2	20	0	excluded	not a RCT	risk of bias not avaialble
9170	UKHSA report 33 (23 december 2021), 2021	2	20	0	excluded	not a RCT	risk of bias not avaialble
9176	UKHSA 31 december 2021, 2021	2	20	0	excluded	not a RCT	risk of bias not avaialble
9214	Southern California (Lewnard), 2022	2	13	0	excluded	not a RCT	risk of bias not avaialble
9216	Sultan, 2022	0	12	0	selection pending
9224	Reynolds, 2022	0	0	0	selection pending
9267	Ostropolets, 2021	0	12	0	selection pending
9294	UKHSA (report W4- 27 January), 2022	2	12	0	excluded	not a RCT	risk of bias not avaialble
9491	Li X, 2022	1	12	0		not a RCT	risk of bias not avaialble
9590	UKHSA report week 12 (24 March 2022), 2022	1	12	0		not a RCT	risk of bias not avaialble